All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

Following the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the Lymphoma Hub spoke with John C. Byrd, OSUCCC −The James, Columbus, US. We asked, Is acalabrutinib superior to ibrutinib for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

Byrd outlines data from the phase III ELEVATE-RR trial, a non-inferiority study which was the first to compare safety and overall survival between the BTK inhibitors acalabrutinib and ibrutinib, in patients with previously treated CLL.


Share: